Sucampo Pharmaceuticals (NASDAQ:SCMP) Upgraded to "Strong-Buy" by ValuEngine

Lloyd Doyle
January 13, 2018

Many analysts are providing their Estimated Earnings analysis for Sucampo Pharmaceuticals, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $0.35/share.

Gauging the level of enthusiasm that Wall Street analysts have for a particular stock is important when considering an investment. During the same quarter in the previous year, the business posted $0.16 EPS.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million for the quarter, compared to analysts' expectations of $58.05 million. (SCMP) delivered a 5.54% surprise with its net revenue. The company had Year Ago Sales of 73.02 Million. Maxim Group reaffirmed a buy rating and issued a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. UBS Group lowered their target price on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a report on Thursday, October 12th.

Sucampo Pharmaceuticals, Inc. (SCMP) stock is now trading 61.91% away from its average-price of 200 days while it maintained a distance of 37.32% from its 50 Days Moving Average and 7.43% compared with the 20 Day Moving Average. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 3rd. Instinet started coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, December 19th. They now have a $15.00 target price on the biopharmaceutical company's stock. Six analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock.

Allegheny Technologies Inc. (ATI) analysts on average have given a price target of $25.15 on ATI stock.

Sucampo Pharmaceuticals (SCMP) traded down $0.35 during trading hours on Wednesday, hitting $18.05. The volume of 1.99 Million shares climbed down over an trading activity of 2.22 Million shares. The stock has a market cap of 867.65 Million. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $18.75. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

Several hedge funds have recently bought and sold shares of the company. 36 funds opened new Sucampo Pharmaceuticals, Inc stakes, 44 increased positions. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. JPMorgan Chase & Co. purchased a new position in Sucampo Pharmaceuticals in the 2nd quarter worth about $117,000.

Over the past three months, Sucampo Pharmaceuticals, Inc. insiders have been net buyers, dumping a net of -97,384 shares. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company's stock valued at $126,000 after purchasing an additional 631 shares during the last quarter. After a recent check, it is observed that the insiders for the firm now own 0.30% shares. Finally, Thrivent Financial For Lutherans lifted its holdings in Sucampo Pharmaceuticals by 11.3% during the second quarter. The stock increased 4.80% or $2.23 during the last trading session, reaching $48.65. The company's institutional ownership is monitored at 74 percent.

Kiener Peter A had sold 50,000 shares worth $825,000 on Thursday, December 7.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

WARNING: This story was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another site, it was stolen and reposted in violation of global copyright & trademark law.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) gross margin percentage stands at 72.8% while its operating margin for the past trailing twelve month is -49.6 percent and its overall profit margin (ttm) is -60.2 Percent. 2017, Sucampo Pharmaceuticals, Inc. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Other reports by Iphone Fresh

Discuss This Article